Key Points
- Director Alan Ezekowitz sold 18,000 shares of Fulcrum Therapeutics at an average price of $3.65, totaling about $65,700. After the sale, he still held 10,927 shares, a 62.23% decrease in ownership.
- FULC shares were down 1.9% and opened at $3.66, giving the company a market cap of about $243.87 million. The stock remains far below its 52-week high of $15.74 and below both its 50-day and 200-day moving averages.
- Analyst sentiment remains cautious: several firms recently downgraded the stock, and MarketBeat says the average rating is “Reduce” with an average price target of $8.20. Institutional ownership remains high at 89.83%.
Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Get Free Report) Director Alan Ezekowitz sold 18,000 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $3.65, for a total transaction of $65,700.00. Following the sale, the director owned 10,927 shares of the company's stock, valued at approximately $39,883.55. This trade represents a 62.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Fulcrum Therapeutics Stock Down 1.9%
Shares of NASDAQ FULC opened at $3.66 on Wednesday. The company has a market capitalization of $243.87 million, a PE ratio of -3.18 and a beta of 2.93. Fulcrum Therapeutics, Inc. has a twelve month low of $2.83 and a twelve month high of $15.74. The firm has a fifty day simple moving average of $5.57 and a 200 day simple moving average of $8.18.
Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings results on Monday, April 27th. The company reported ($0.25) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.06. As a group, equities analysts expect that Fulcrum Therapeutics, Inc. will post -0.67 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several equities research analysts recently commented on the company. Cantor Fitzgerald cut Fulcrum Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, June 2nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Fulcrum Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen raised Fulcrum Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Saturday, May 2nd. Leerink Partners cut Fulcrum Therapeutics from an "outperform" rating to a "market perform" rating and set a $4.00 price target on the stock. in a report on Tuesday, June 2nd. Finally, Piper Sandler downgraded shares of Fulcrum Therapeutics from an "overweight" rating to a "neutral" rating and set a $3.00 price objective for the company. in a research report on Tuesday, June 2nd. One research analyst has rated the stock with a Buy rating, seven have assigned a Hold rating and four have assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Reduce" and an average target price of $8.20.
Get Our Latest Research Report on Fulcrum Therapeutics
Institutional Investors Weigh In On Fulcrum Therapeutics
A number of institutional investors have recently added to or reduced their stakes in FULC. Seven Fleet Capital Management LP bought a new position in shares of Fulcrum Therapeutics in the first quarter valued at approximately $292,000. Westshore Wealth LLC bought a new stake in Fulcrum Therapeutics during the first quarter worth $130,000. The Manufacturers Life Insurance Company boosted its position in Fulcrum Therapeutics by 25.0% in the first quarter. The Manufacturers Life Insurance Company now owns 16,102 shares of the company's stock worth $124,000 after purchasing an additional 3,219 shares during the last quarter. Pale Fire Capital SE purchased a new position in Fulcrum Therapeutics in the first quarter worth $200,000. Finally, Siren L.L.C. grew its stake in Fulcrum Therapeutics by 20.5% in the 1st quarter. Siren L.L.C. now owns 2,350,000 shares of the company's stock valued at $18,024,000 after purchasing an additional 400,000 shares during the period. 89.83% of the stock is owned by institutional investors.
About Fulcrum Therapeutics
(
Get Free Report)
Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company's core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.
Fulcrum's most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
